OTEZLA REDUCES TENDER AND SWOLLEN JOINTS1

Sustained reduction in tender and swollen joint count up to 4 years1,a

aPALACE 1 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Randomized patients who received ≥1 dose of study medication: OTEZLA 30 mg BID, n = 168; placebo, n = 168. The n at each time point represents the number of patients with available data at the time point.

ACR20 response rates were sustained for up to 4 years in patients receiving OTEZLA 30mg BID‡

*PALACE 1-3 pooled analysis. Per-protocol population, LOCF.

†PALACE 1 study. Per-protocol population, LOCF.

‡PALACE 1 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.

Psoriatic Arthritis

Disclaimer: This is an international website for OTEZLA® (apremilast). The information on this site is not country-specific. It may contain information that is outside the approved indications in the country in which you are located. If you are a US resident, please click on the US residents link at the top of this page.